Concurrent gastrointestinal perforation and pulmonary embolism due to bevacizumab in an adult undergoing treatment for stage IV colon cancer.
Bevacizumab is an important component in the treatment of metastatic colorectal cancer when used with 5-fluorouracil, leucovorin and oxaliplatin or irinotecan. As a molecular target agent, it is considered to be less toxic than traditional chemotherapy; however, bevacizumab has been shown to cause serious, life-threatening adverse effects. The following report describes a case of bevacizumab-associated pulmonary embolism with simultaneous gastrointestinal perforation in a patient with stage IV adenocarcinoma of the descending colon. This case report and literature review describes the risk factors, etiology, and typical presentation of bevacizumab-induced gastrointestinal perforation and pulmonary embolism.
1 Scott & White Memorial Hospital, Department of Pharmacy, Baylor Scott & White Health, Temple, TX, USA.
Sana
S
Qureshi
2 Scott & White Memorial Hospital, Department of Radiology, Baylor Scott & White, Temple, TX, USA.
Ryan B
RB
Elliott
1 Scott & White Memorial Hospital, Department of Pharmacy, Baylor Scott & White Health, Temple, TX, USA.|3 Texas A&M Health Science Center, College of Medicine, Temple, TX, USA.
Jon D
JD
Herrington
D000328:Adult; D000074322:Antineoplastic Agents, Immunological / Q000008:administration & dosage / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects; D000068258:Bevacizumab / Q000008:administration & dosage / Q000009:adverse effects*; D003110:Colonic Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy*; D041981:Gastrointestinal Tract / Q000000981:diagnostic imaging / Q000187:drug effects / Q000293:injuries; D006801:Humans; D007416:Intestinal Perforation / Q000139:chemically induced* / Q000000981:diagnostic imaging; D008297:Male; D009367:Neoplasm Staging; D011655:Pulmonary Embolism / Q000139:chemically induced* / Q000000981:diagnostic imaging; D016896:Treatment Outcome
D000074322:Antineoplastic Agents, Immunological; D000068258:Bevacizumab
Bevacizumab; colorectal cancer; gastrointestinal perforation; pulmonary embolism; thromboembolism